Chris Shibutani
Stock Analyst at Goldman Sachs
(3.59)
# 790
Out of 5,170 analysts
94
Total ratings
56.25%
Success rate
23.85%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $53.98 | +85.25% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $15.26 | -80.34% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $9.08 | +65.20% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.40 | +12.68% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $89.31 | +53.40% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $24.00 | +37.50% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $527.00 | -42.69% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $45.53 | +12.01% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $237.60 | -34.76% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $14.05 | -71.53% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $6.27 | +218.98% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $917.50 | -21.20% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $12.20 | +113.11% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $129.70 | +17.96% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $206.23 | -16.11% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $74.84 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $58.11 | +18.74% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $22.09 | -41.15% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $99.29 | -76.84% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $79.57 | -34.65% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $27.41 | +118.90% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $11.98 | +50.25% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $19.32 | -12.01% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.50 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.15 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $53.98
Upside: +85.25%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $15.26
Upside: -80.34%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $9.08
Upside: +65.20%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.40
Upside: +12.68%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $89.31
Upside: +53.40%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $24.00
Upside: +37.50%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $527.00
Upside: -42.69%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $45.53
Upside: +12.01%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $237.60
Upside: -34.76%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $14.05
Upside: -71.53%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $6.27
Upside: +218.98%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $917.50
Upside: -21.20%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $12.20
Upside: +113.11%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $129.70
Upside: +17.96%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $206.23
Upside: -16.11%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $74.84
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $58.11
Upside: +18.74%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $22.09
Upside: -41.15%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $99.29
Upside: -76.84%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $79.57
Upside: -34.65%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.41
Upside: +118.90%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.98
Upside: +50.25%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $19.32
Upside: -12.01%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.50
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.15
Upside: -